Moors & Cabot’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.35M | Sell |
54,313
-959
| -2% | -$79.1K | 0.19% | 114 |
|
|
2025
Q4 | $4.71M | Buy |
55,272
+945
| +2% | +$77.6K | 0.2% | 101 |
|
|
2025
Q3 | $4.23M | Buy |
54,327
+578
| +1% | +$45.2K | 0.18% | 107 |
|
|
2025
Q2 | $4.2M | Buy |
53,749
+225
| +0.4% | +$16.8K | 0.2% | 105 |
|
|
2025
Q1 | $3.88M | Sell |
53,524
-1,065
| -2% | -$76.2K | 0.2% | 106 |
|
|
2024
Q4 | $4.04M | Buy |
54,589
+152
| +0.3% | +$10.6K | 0.19% | 105 |
|
|
2024
Q3 | $3.59M | Sell |
54,437
-75
| -0.1% | -$5.45K | 0.18% | 113 |
|
|
2024
Q2 | $5.04M | Buy |
54,512
+1,063
| +2% | +$94.1K | 0.27% | 85 |
|
|
2024
Q1 | $5.11M | Buy |
53,449
+2,950
| +6% | +$248K | 0.28% | 80 |
|
|
2023
Q4 | $3.85M | Buy |
50,499
+1,584
| +3% | +$110K | 0.24% | 95 |
|
|
2023
Q3 | $3.39M | Sell |
48,915
-705
| -1% | -$56.7K | 0.23% | 100 |
|
|
2023
Q2 | $4.68M | Buy |
49,620
+208
| +0.4% | +$18.1K | 0.31% | 74 |
|
|
2023
Q1 | $4.09M | Buy |
49,412
+652
| +1% | +$51.3K | 0.28% | 87 |
|
|
2022
Q4 | $3.64M | Buy |
48,760
+80
| +0.2% | +$6.17K | 0.25% | 91 |
|
|
2022
Q3 | $4.02M | Sell |
48,680
-1,572
| -3% | -$151K | 0.31% | 80 |
|
|
2022
Q2 | $4.78M | Sell |
50,252
-62
| -0.1% | -$6.42K | 0.34% | 70 |
|
|
2022
Q1 | $5.92M | Sell |
50,314
-1,025
| -2% | -$115K | 0.36% | 60 |
|
|
2021
Q4 | $6.65M | Sell |
51,339
-1,863
| -4% | -$217K | 0.41% | 52 |
|
|
2021
Q3 | $6.02M | Sell |
53,202
-322
| -0.6% | -$36.8K | 0.38% | 59 |
|
|
2021
Q2 | $5.54M | Buy |
53,524
+434
| +0.8% | +$40.9K | 0.39% | 60 |
|
|
2021
Q1 | $4.44M | Sell |
53,090
-1,660
| -3% | -$140K | 0.34% | 66 |
|
|
2020
Q4 | $4.99M | Sell |
54,750
-667
| -1% | -$55.3K | 0.42% | 55 |
|
|
2020
Q3 | $4.42M | Buy |
55,417
+186
| +0.3% | +$14.5K | 0.42% | 57 |
|
|
2020
Q2 | $3.81M | Sell |
55,231
-1,823
| -3% | -$130K | 0.41% | 60 |
|
|
2020
Q1 | $3.59M | Sell |
57,054
-4,311
| -7% | -$311K | 0.52% | 46 |
|
|
2019
Q4 | $4.77M | Sell |
61,365
-2,415
| -4% | -$189K | 0.48% | 48 |
|
|
2019
Q3 | $4.67M | Buy |
63,780
+2,148
| +3% | +$151K | 0.51% | 46 |
|
|
2019
Q2 | $3.79M | Buy |
61,632
+1,242
| +2% | +$75.1K | 0.48% | 51 |
|
|
2019
Q1 | $3.85M | Buy |
60,390
+1,563
| +3% | +$89.2K | 0.52% | 44 |
|
|
2018
Q4 | $3.01M | Buy |
58,827
+6,030
| +11% | +$305K | 0.47% | 53 |
|
|
2018
Q3 | $3.06M | Buy |
52,797
+4,614
| +10% | +$226K | 0.37% | 69 |
|
|
2018
Q2 | $2.34M | Buy |
48,183
+729
| +2% | +$34K | 0.32% | 87 |
|
|
2018
Q1 | $2.21M | Sell |
47,454
-15,759
| -25% | -$684K | 0.29% | 88 |
|
|
2017
Q4 | $2.38M | Sell |
63,213
-198
| -0.3% | -$7.27K | 0.32% | 88 |
|
|
2017
Q3 | $2.31M | Sell |
63,411
-5,295
| -8% | -$202K | 0.33% | 84 |
|
|
2017
Q2 | $2.7M | Sell |
68,706
-1,707
| -2% | -$62.3K | 0.45% | 54 |
|
|
2017
Q1 | $2.21M | Sell |
70,413
-4,200
| -6% | -$131K | 0.37% | 71 |
|
|
2016
Q4 | $2.32M | Sell |
74,613
-600
| -0.8% | -$19.4K | 0.38% | 66 |
|
|
2016
Q3 | $3.01M | Sell |
75,213
-900
| -1% | -$33.9K | 0.5% | 50 |
|
|
2016
Q2 | $2.54M | Sell |
76,113
-2,190
| -3% | -$74.9K | 0.45% | 56 |
|
|
2016
Q1 | $2.29M | Sell |
78,303
-1,155
| -1% | -$31.9K | 0.41% | 65 |
|
|
2015
Q4 | $2.11M | Sell |
79,458
-10,398
| -12% | -$270K | 0.39% | 66 |
|
|
2015
Q3 | $2.11M | Sell |
89,856
-804
| -0.9% | -$19.4K | 0.39% | 67 |
|
|
2015
Q2 | $2.13M | Sell |
90,660
-1,200
| -1% | -$27.1K | 0.35% | 72 |
|
|
2015
Q1 | $2.16M | Sell |
91,860
-3,600
| -4% | -$80.8K | 0.36% | 72 |
|
|
2014
Q4 | $2.01M | Sell |
95,460
-1,620
| -2% | -$32.5K | 0.34% | 78 |
|
|
2014
Q3 | $1.64M | Buy |
97,080
+600
| +0.6% | +$9.47K | 0.28% | 92 |
|
|
2014
Q2 | $1.38M | Buy |
+96,480
| New | +$1.31M | 0.23% | 107 |
|
Other funds holding EW
VCM
VPM
Moors & Cabot's EW Position: Q1 2026 in Review
Moors & Cabot reduced its Edwards Lifesciences (EW) stake by 1.7% in Q1 2026, selling an estimated $79.1K and leaving 54,313 shares worth $4.35M. The position accounts for 0.19% of the portfolio, ranked #114.
Moors & Cabot first reported a position in EW in Q2 2014 and has held it in 48 quarters since. The position peaked at $6.65M in Q4 2021. 1,287 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Moors & Cabot held 54,313 shares of Edwards Lifesciences worth $4.35M as of Q1 2026.
- Moors & Cabot sold 959 Edwards Lifesciences shares in Q1 2026, an estimated $79.1K.
- Edwards Lifesciences made up 0.19% of Moors & Cabot's portfolio in Q1 2026, its #114 holding.
- Moors & Cabot first reported a position in Edwards Lifesciences in Q2 2014 and has held it in 48 quarters since.
- Moors & Cabot's Edwards Lifesciences position peaked at $6.65M in Q4 2021.
- 1,287 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.